ABLi reports biomarker findings from risvodetinib study for Parkinson’s

ABLi Therapeutics has completed a detailed biomarker analysis of risvodetinib for Parkinson’s disease in the Phase II 201 Trial. The post ABLi reports biomarker findings from risvodetinib study for Parkinson’s appeared first on Clinical Trials Arena .